Stock NUVB NUVATION BIO INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Nuvation Bio Inc.

Equities

NUVB

US67080N1019

Biotechnology & Medical Research

Market Closed - Nyse
Other stock markets
 04:00:02 2024-05-24 pm EDT 		5-day change 1st Jan Change
3.08 USD 0.00% Intraday chart for Nuvation Bio Inc. -7.23% +103.97%
May. 14 Nuvation Bio Q1 Loss Narrows; Shares Fall After Hours MT
May. 14 Nuvation Bio Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Business Summary

Nuvation Bio Inc. is a biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. The Company is advancing multiple clinical-stage candidates, including a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, a bromodomain and extra-terminal (BET) inhibitor, and a drug-drug conjugate (DDC). Its portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Taletrectinib is an oral, potent, CNS-active, selective, ROS1 inhibitor specifically designed for the potential treatment of ROS1-positive non-small cell lung cancer (NSCLC). Safusidenib is an oral, potent, targeted inhibitor of mIDH1 being evaluated in a global Phase II trial in patients with low-grade IDH1-mutant glioma. NUV-868 is a BD2-selective oral small molecule BET inhibitor, that inhibits BRD4. It is conducting Phase I/II study of NUV-1511.

Number of employees: 159

Managers

Managers TitleAgeSince
David Hung FOU
 Founder 66 18-03-19
Moses Makunje DFI
 Director of Finance/CFO 46 20-06-30
Dong Fang Liu CTO
 Chief Tech/Sci/R&D Officer 54 22-07-17
Gary Hattersley CTO
 Chief Tech/Sci/R&D Officer 57 19-05-31
David Hanley PRN
 Corporate Officer/Principal 54 21-05-31
Stacy Markel HRO
 Human Resources Officer 59 19-09-30
Kerry Wentworth LAW
 General Counsel 51 22-07-17

Members of the board

Members of the board TitleAgeSince
David Hung FOU
 Founder 66 18-03-19
Kim Blickenstaff BRD
 Director/Board Member 71 19-07-31
Kathryn Falberg BRD
 Director/Board Member 63 20-09-30
Daniel Welch CHM
 Chairman 66 20-06-30
Robert D. Mashal BRD
 Director/Board Member - Jan. 07
Tony Vernon BRD
 Director/Board Member 68 19-05-31
Robert Bazemore BRD
 Director/Board Member 56 20-06-30

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 1,000,000 0 0 72.50 %
Stock B 1 246,170,648 179,186,791 ( 72.79 %) 0
Stock C 0 851,202 0 0

Shareholders

NameEquities%Valuation
David Hung
26.73 %
58,281,054 26.73 % 153 M $
Fidelity Management & Research Co. LLC
12.72 %
27,737,077 12.72 % 73 M $
EcoR1 Capital, LLC
8.810 %
19,209,643 8.810 % 50 M $
Omega Fund Management LLC
6.454 %
14,072,340 6.454 % 37 M $
Vanguard Fiduciary Trust Co.
3.455 %
7,534,148 3.455 % 20 M $
Decheng Capital LLC
2.831 %
6,172,344 2.831 % 16 M $
Abrams Capital Management LP
1.748 %
3,811,513 1.748 % 10 M $
Tang Capital Management LLC
1.629 %
3,551,864 1.629 % 9 M $
Geode Capital Management LLC
1.434 %
3,127,198 1.434 % 8 M $
STATE STREET CORPORATION
1.396 %
3,043,510 1.396 % 8 M $
NameEquities%Valuation
David Hung
6.368 %
1,000,000 6.368 % 3 M $
NameEquities%Valuation
BlackRock Advisors LLC
-
12,168,499 - 3 M $
Citadel Securities GP LLC
-
2,190,689 - 613 393 $
Barclays Bank Plc
-
1,607,344 - 450 056 $
EcoR1 Capital, LLC
-
963,333 - 269 733 $
683 Capital Management LLC
-
610,723 - 171 002 $
BlackRock Investment Management LLC
-
456,672 - 127 868 $
Franklin Advisers, Inc.
-
394,349 - 110 418 $
Greenland Capital Management LP
-
344,660 - 96 505 $
Boxer Capital LLC
-
266,666 - 74 666 $
Adage Capital Partners GP LLC
-
266,666 - 74 666 $

Company contact information

Nuvation Bio, Inc.

1500 Broadway Suite 1401

10036, New York

+

http://www.nuvationbio.com
address Nuvation Bio Inc.(NUVB)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
3.08 USD
Average target price
6.6 USD
Spread / Average Target
+114.29%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
NUVATION BIO INC. Stock Nuvation Bio Inc.
+103.97% 761M
MODERNA, INC. Stock Moderna, Inc.
+67.53% 63.85B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-0.77% 41.83B
LONZA GROUP AG Stock Lonza Group AG
+45.66% 40.65B
CELLTRION, INC. Stock Celltrion, Inc.
-10.72% 27.12B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+13.30% 26.52B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.79% 18.69B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+4.70% 12.73B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+24.10% 12.11B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.41% 12.07B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. NUVB Stock
  4. Company Nuvation Bio Inc.